We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Novel Psychedelic Approaches to Treating Mental Health Conditions

Novel Approaches to Treating Mental Health Conditions

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of New Chemical Entities (NCE) for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next-generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.

Joseph Tucker, PhD
Joseph Tucker, PhD
Enveric Biosciences Inc.
Register for FREE Now!
Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar